Inotuzumab ozogamicin followed by blinatumomab without chemotherapy showed high remission and survival rates in older patients with Ph-negative B-cell ALL. The regimen achieved a CR by the end of blinatumomab in 97% of patients and a 12-month event-free survival of 75%, representing a significant improvement over historical outcomes with conventional therapies.
Study
|
Phase II study [Alliance A041703] |
| Older patients with untreated Ph-negative, CD22-positive B-cell ALL |
| Inotuzumab ozogamicin x 2 (n=33) followed by blinatumomab x 4-5
|
Efficacy
|
CR: 85% after inotuzumab ozogamicin, 97% by end of blinatumomab |
| 1-yr EFS: 75% (HR 0.28) |
| 12-mo OS: 85%
|
Safety
|
Grade >=3 AEs: Cytopenias, Febrile neutropenia |
| Encephalopathy: 9% with blinatumomab |
| One induction death due to respiratory failure and liver complications
|
J Clin Oncol 2025;43:3526-3535
http://doi.org/10.1200/JCO-25-00307
Reviewed by Ulas D. Bayraktar, MD on Nov 15, 2025
